Canada-based OncoQuest has started enrolling patients in a Phase I/II clinical trial to evaluate the combination of its antibody oregovomab with Hiltonol as a treatment for ovarian cancer.

Oregovomab is a high-affinity monoclonal antibody, which is being developed to bind to tumour-associated antigen CA125 (MUC16) and trigger an immune response.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hiltonol is an investigational agonist of TLR3 and acts as an immune adjuvant.

Managed and monitored by US-based clinical research organisation (CRO) Veristat, the Phase I/II trial is being conducted at Florida Hospital Cancer Institute in Orlando and at Virginia Commonwealth University's Massey Cancer Centre in Richmond.

"Oregovomab is a high-affinity monoclonal antibody, which is being developed to bind to tumour-associated antigen CA125."

The trial will assess the use of oregovomab when administered as a combination therapy with an immune adjuvant in a recurrent setting.

See Also:

Oregovomab is also being investigated in another Phase I/II trial that commenced in May this year. This trial is studying Oregovomab in combination with a checkpoint inhibitor called nivolumab for recurrent ovarian cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OncoQuest CEO Dr Madiyalakan said: "Hiltonol is an investigational TLR3 agonist that has been found to stimulate both cellular and humoral immune response, and is being tested as an immune adjuvant in a number of oncology studies.

"We will evaluate the outcome from this study and our other study using a checkpoint inhibitor combination to identify how best to utilise oregovomab in this important clinical setting.”